Meeting
2013 ASCO Annual Meeting
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
Authors
Mark Danese
Outcomes Insights, Inc., Westlake Village, CA
Mark Danese , Deepa Lalla , Melissa Brammer , Eduardo Santos , Abraham Lee , Anthony Masaquel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 625)
DOI
10.1200/jco.2013.31.15_suppl.625
Abstract #
625
Poster Bd #
11H
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Elevated pretreatment serum biomarkers and correlation with progression-free (PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer.
First Author: Suhail M. Ali
Poster
2022 ASCO Annual Meeting
Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016.
First Author: Zhonghui Ou
Poster
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
First Author: Marcela Carausu
Poster
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
First Author: Matthew Loft